These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 11378657)

  • 21. Binding of tissue factor pathway inhibitor to cultured endothelial cells-influence of glycosaminoglycans.
    Iversen N; Sandset PM; Abildgaard U; Torjesen PA
    Thromb Res; 1996 Nov; 84(4):267-78. PubMed ID: 8948051
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Overview: from heparin to low molecular weight heparin: beyond anticoagulation.
    Mousa SA; Fareed J
    Curr Opin Investig Drugs; 2001 Aug; 2(8):1077-80. PubMed ID: 11892916
    [No Abstract]   [Full Text] [Related]  

  • 23. The effect of heparin and other glycosaminoglycans on levels of tissue plasminogen activator and plasminogen activator inhibitor in cultured human umbilical vein endothelial cells.
    Marsh NA; Minter AJ; Chesterman CN
    Blood Coagul Fibrinolysis; 1990 Jun; 1(2):133-8. PubMed ID: 1966669
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The potential of the molecular diversity of heparin and heparan sulfate for drug development.
    Fügedi P
    Mini Rev Med Chem; 2003 Nov; 3(7):659-67. PubMed ID: 14529507
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In vivo effects of low molecular weight heparins on experimental thrombosis and bleeding.
    Hirsh J
    Haemostasis; 1986; 16(2):82-6. PubMed ID: 3710297
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Anti-inflammatory properties of a heparin-like glycosaminoglycan with reduced anti-coagulant activity isolated from a marine shrimp.
    Brito AS; Arimatéia DS; Souza LR; Lima MA; Santos VO; Medeiros VP; Ferreira PA; Silva RA; Ferreira CV; Justo GZ; Leite EL; Andrade GP; Oliveira FW; Nader HB; Chavante SF
    Bioorg Med Chem; 2008 Nov; 16(21):9588-95. PubMed ID: 18835720
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Heparan sulfate and heparin as a potentiator or a suppressor of growth of normal and transformed vascular endothelial cells.
    Imamura T; Mitsui Y
    Exp Cell Res; 1987 Sep; 172(1):92-100. PubMed ID: 2958303
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Structural features of dermatan sulfates and their relationship to anticoagulant and antithrombotic activities.
    Linhardt RJ; al-Hakim A; Liu JA; Hoppensteadt D; Mascellani G; Bianchini P; Fareed J
    Biochem Pharmacol; 1991 Sep; 42(8):1609-19. PubMed ID: 1930287
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Glycosaminoglycan backbone is not required for the modulation of hemostasis: effect of different heparin derivatives and non-glycosaminoglycan analogs.
    Bouças RI; Jarrouge-Bouças TR; Lima MA; Trindade ES; Moraes FA; Cavalheiro RP; Tersariol IL; Hoppenstead D; Fareed J; Nader HB
    Matrix Biol; 2012 Jun; 31(5):308-16. PubMed ID: 22504459
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Structural and conformational aspects of the anticoagulant and anti-thrombotic activity of heparin and dermatan sulfate.
    Casu B; Guerrini M; Torri G
    Curr Pharm Des; 2004; 10(9):939-49. PubMed ID: 15078125
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Binding of heparin and compound Y to endothelial cells stimulates the synthesis of an antithrombotic heparan sulfate proteoglycan.
    Pinhal MA; Silva IF; Lee TC; Dietrich CP; Nader HB
    Braz J Med Biol Res; 1994 Sep; 27(9):2191-5. PubMed ID: 7787803
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Orgaran (Org 10172): its pharmacological profile in experimental models.
    Meuleman DG
    Haemostasis; 1992; 22(2):58-65. PubMed ID: 1379965
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of glycosaminoglycans on U-937 leukemia cell proliferation and differentiation: structure-function relationship.
    Volpi N; Petrini M; Conte A; Valentini P; Venturelli T; Bolognani L; Ronca G
    Exp Cell Res; 1994 Nov; 215(1):119-30. PubMed ID: 7957660
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Isolation and characterization of heparin from tuna skins.
    Jeske WP; McDonald MK; Hoppensteadt DA; Bau EC; Mendes A; Dietrich CP; Walenga JM; Coyne E
    Clin Appl Thromb Hemost; 2007 Apr; 13(2):137-45. PubMed ID: 17456622
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Study of low molecular weight heparin effect on the relation between anticoagulant activity and antithrombin III affinity.
    Hamano S; Nishiyama M; Kikuchi S; Komatsu H; Miyata H; Ikeda S; Sakuragawa N
    Thromb Res; 1992 May; 66(4):299-307. PubMed ID: 1329257
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Heparin and low molecular weight heparins as scaffolds for assembling antithrombin and serine proteases.
    Ofosu FA
    Thromb Res; 2008; 123(1):5-7. PubMed ID: 18284938
    [No Abstract]   [Full Text] [Related]  

  • 37. A non-hemorrhagic hybrid heparin/heparan sulfate with anticoagulant potential.
    Brito AS; Cavalcante RS; Palhares LC; Hughes AJ; Andrade GP; Yates EA; Nader HB; Lima MA; Chavante SF
    Carbohydr Polym; 2014 Jan; 99():372-8. PubMed ID: 24274520
    [TBL] [Abstract][Full Text] [Related]  

  • 38. New antithrombotic agents for the prevention and treatment of deep vein thrombosis.
    Boneu B
    Haemostasis; 1996 Oct; 26 Suppl 4():368-78. PubMed ID: 8979141
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Interaction of heparan sulfate and its fractions with endothelial cells in culture.
    Tiozzo R; Cingi MR; Croce MA
    Int J Tissue React; 1993; 15(4):163-8. PubMed ID: 8188456
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Heparin also interacts with selectins and modulates the cell adhesion process.
    Yanaka K; Kato N; Nose T
    Circulation; 2000 Nov; 102(20):E169. PubMed ID: 11076839
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.